TriSalus Life Sciences, Inc.(TLSI)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

TriSalus Life Sciences, Inc. (TLSI) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TLSI at 29.7/100 on a 32-signal composite quality model, placing it at rank #2,524 of 2,962 stocks — the bottom half of the AI-ranked universe. TLSI scores in the top quartile across revenue growth (90.8). Areas of concern include balance sheet strength (3.1) and revenue scale (8.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 8.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), TriSalus Life Sciences, Inc. reports quarterly revenue of $11.4M, net income of $-9.2M, free cash flow of $-10.2M. Top institutional holders of TLSI by reported 13-F value include First Light Asset Management, BlackRock, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. TLSI trades on the Nasdaq exchange and files with the SEC under CIK 1826667. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TLSI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for TriSalus Life Sciences, Inc. directly from SEC EDGAR.